MRSA: treating people with infection

Keyphrases

• Methicillin-resistant Staphylococcus Aureus 100%
• Methicillin 66%
• Cephalosporins 66%
• β-lactamase Inhibitor 66%
• June 2014 33%
• Northern Ireland 33%
• Wales 33%
• MEDLINE 33%
• Embase 33%
• Hospital Admission 33%
• Cochrane Library 33%
• Antibiotic Use 33%
• Clinical Evidence 33%
• Staphylococcus Aureus 33%
• Methicillin-resistant Staphylococcus Aureus Infection 33%
• β-lactam Antibiotics 33%
• Blood Culture 33%
• Flucloxacillin 33%
• Conference Abstracts 33%
• Body Sites 33%
• Carbapenems 33%
• Linezolid 33%
• Underlying Disease 33%
• Daptomycin 33%
• Tigecycline 33%
• Deduplication 33%
• Comment Sections 33%
• Full Publication 33%
• Ceftobiprole 33%
• Ceftaroline 33%
• Streptogramins 33%
• Quinupristin-dalfopristin 33%
• Grade Estimation 33%
• Pristinamycin 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Methicillin-Resistant Staphylococcus Aureus 100%
• Meticillin 66%
• Cephalosporin Derivative 66%
• Randomized Controlled Trial 33%
• Staphylococcus Aureus 33%
• Beta Lactam 33%
• Beta Lactam Antibiotic 33%
• Methicillin Resistant Staphylococcus Aureus Infection 33%
• Flucloxacillin 33%
• Linezolid 33%
• Carbapenem Derivative 33%
• Tigecycline 33%
• Daptomycin 33%
• Beta Lactamase Inhibitor 33%
• Ceftaroline 33%
• Streptogramin Derivative 33%
• Ceftobiprole 33%
• Pristinamycin 33%
• Dalfopristin Plus Quinupristin 33%
• Diseases 33%